

**EchoSolv™ to be made available to
700 US cardiovascular facilities
through Studycast integration agreement**

Highlights:

- **Integration Partner agreement with Core Sound Imaging**
- **Core Sound Imaging supplies Studycast to medical facilities in 49 US states and territories and 7 countries**
- **Agreement will see EchoSolv™ integration made available to 700 cardiovascular facilities**
- **EchoSolv™ to be integrated into Studycast imaging and reporting platform**
- **Rapid uptake to be supported by strong presence at ASE Conference, June 2023**

Sydney: AI and Medical Technology company Echo IQ (“the Company”) (ASX:EIQ) is pleased to announce an agreement with Core Sound Imaging, Inc. (“Core Sound Imaging”) of Raleigh, North Carolina, US. Core Sound Imaging supplies the comprehensive imaging workflow platform, Studycast, to medical facilities in 49 US states and territories and 7 countries. This agreement will see an out-of-box integration with EchoSolv™ made available to all users of Studycast, within existing workflows, and is expected to fast-track adoption of Echo IQ’s innovation AI-backed solutions to hospitals and clinical practices.

About Core Sound Imaging and Studycast

Since 2007, Core Sound Imaging has provided leading-edge solutions for medical imaging workflow, including image storage, a zero-footprint viewer, and a robust suite of interpretation and structured reporting tools. The company is recognised to have transformed the manual entry of medical data into automated data population and reporting for a more intuitive and streamlined user workflow.

The Studycast system is the flagship solution from Core Sound Imaging with capabilities that go beyond those of a traditional Picture Archiving and Communication System (PACS). It is a comprehensive imaging workflow solution that provides a single, unified workflow from exam to archive and allowing clients to work from anywhere, anytime.

Integration of EchoSolv™ into Studycast

Under the terms of the one-year agreement, EchoSolv™ will be integrated into the Studycast system. Echo IQ will remain responsible for the direct sale of EchoSolv™ to prospective users, however access to EchoSolv™ will be simple and fast with this new turnkey integration interface. User benefits of this agreement include:

1. Every user of Studycast will have access to the integration, enabling them to leverage the diagnostic support power of EchoSolv™;
2. Users will be able to embed EchoSolv™ assessments into current reporting; and
3. Technical integration for mutual customers of EchoSolv™ and Studycast is no longer necessary with access via built-in integration.

The agreement gives Echo IQ several important benefits as commercial roll-out of EchoSolv™ accelerates. Studycast customers will be able to gain access to EchoSolv™ almost instantly. They can do so with zero additional technical integration required, and they can see EchoSolv™ assessments directly embedded into their existing diagnostic workflow. To fast-track user awareness, EchoSolv™ will be showcased by Core Sound Imaging at the upcoming ASE 2023 cardiology conference in National Harbor, MD, giving prospective customers an in-person tour of the solution.

Key Terms of the Agreement

The agreement between the Company and Core Sound Imaging is for the Company's EchoSolv™ solution to be integrated into the Studycast platform. Pursuant to the agreement, the Company will pay Core Sound Imaging an integration licensing fee.

New and existing users will be able to access EchoSolv™ via the Studycast platform by entering into a direct sale with the Company. This agreement is for an initial term of 1 year, commencing immediately on completion of an integration verification period, expected to last approximately 8 weeks. The agreement includes standard commercial terms for a contract of this nature including termination on 30 days written notice.

At this stage, the Company is unable to provide any meaningful guidance as to the potential financial impact arising from this agreement. The financial impact will be dependent on the degree of commercial uptake of the EchoSolv™ solution by current and new users of Studycast. User uptake will be a key focus of the Company's US based sales team over the coming months.

Comments

Core Sound Imaging COO and founding partner, Laurie Smith, said: *“We expect our Studycast clients to benefit immediately from the AI-backed decision support capability of EchoSolv™. Having the flexibility to use this novel technology without the complexities of manual set-up will make the adoption of AI in cardiovascular care easier and simpler than many may have imagined. We are delighted to be showcasing EchoSolv™ later this month at ASE 2023 (the American Society of Echocardiology Conference) and expect our customers to embrace this important solution as part of the Studycast Integration Program.”*

Echo IQ Executive Chair, Andrew Grover, added: *“Studycast has significant market penetration in US cardiovascular hospitals and this established presence and trust delivers and outstanding commercial opportunity to Echo IQ given Core Sound Imaging’s acceptance of our technology. The value of this two-year agreement should not be underestimated by our shareholders and it is further validation of EchoSolv™. Commercial take up of EchoSolv™ is gathering pace in the US and Australia and we anticipate more revenue-generating deployments to be reported shortly.”*

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.